Results 41 to 50 of about 29,392 (188)

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain

PLoS ONE, 2021
Background/Objective AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in ...
Simone Rivolo, Manuela Di Fusco, Carlos Polanco, Amiee Kang, Devender Dhanda, Mirko Savone, Aristeidis Skandamis, Thitima Kongnakorn, Javier Soto   +8 more
doaj   +2 more sources

Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5‐year analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Careful consideration of drug–drug interactions (DDIs) is critical as people with HIV age. We analysed queries submitted to the University of Liverpool HIV Drug Interactions Database to assess changes in prescribing patterns over 5 years. Methods Queries submitted between January 2020 and December 2024 were extracted and categorized by year ...
Cecile Gras, Minh P. Le, Justin Chiong, Sara Gibbons, Daniel Seddon, Catia Marzolini, Saye Khoo   +6 more
wiley   +1 more source

Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling

British Journal of Clinical Pharmacology, EarlyView.
Aim Temporal shifts in patient characteristics can influence comparative treatment effects within a certain indication. We investigated patient characteristics and comparative effectiveness and safety for direct oral anticoagulants (DOACs) and warfarin over the time period where DOACs replaced warfarin as preferred stroke prophylaxis in patients with ...
Raoul B. L. J. van den Hemel, Aernoud T. L. Fiolet, Magdalena A. Gamba, Patrick C. Souverein, Olaf H. Klungel, Lourens T. Bloem, Sophie H. Bots   +6 more
wiley   +1 more source

APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE

Атеротромбоз, 2017
Apixaban is the only NOA the administration of which is associated with a reduction in the incidence of both stroke and major bleeding. Therefore, apixaban is the drug of choice in patients with non-valvular AF, including elderly patients, patients with ...
O. O. Shakhmatova, E. P. Panchenko
doaj   +1 more source

Apixaban-induced leukocytoclastic vasculitis

, 2020
SummaryIntroduction:Drug-induced vasculitis is a rare adverse drug reaction and the potential to induce such a reaction is often established postmarketing.
Schmidt, Jakob Nøhr, Damkier, Per; id_orcid, Per Damkier, Peter Esbech, Esbech, Peter, Lone Kærslund Andersen, Jakob Nøhr Schmidt, Andersen, Lone Kærslund   +7 more
core   +1 more source

Accelerating green heterocyclic synthesis: Convergence of AI, automation, and sustainable chemistry

Bulletin of the Korean Chemical Society, EarlyView.
Green heterocyclic synthesis and data‐driven tools such as AI, high‐throughput experimentation, continuous flow, and self‐driving laboratories have developed largely in parallel. This review connects them and asks how green metrics such as E‐factor and PMI might serve as explicit optimization targets rather than post‐hoc measures, toward sustainable ...
Noor Aisyah Ahmad Shah, Amirreza Mottafegh, Su‐Hyun Yoo, Jongwoon Kim, Minseon Byeon, Juhwan Noh, Yea‐Lee Lee, Jin Suk Myung, Gwang‐Noh Ahn   +8 more
wiley   +1 more source

Virtual Twin Approach Using Physiologically Based Pharmacokinetic Modeling to Support Precision Dosing of Valproic Acid in Geriatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang, Dong‐Gyu Heo, Eunjin Hong   +2 more
wiley   +1 more source

Therapeutic Drug Monitoring of Apixaban Using Chromogenic Kits [PDF]

, 2020
Apixaban is a novel oral anticoagulant that prevents clotting by directly inhibiting Factor Xa in the coagulation cascade. Due to its different pharmacokinetics, previous standards for testing anticoagulant concentrations are ineffective at measuring ...
Vogel, Brooke
core   +1 more source

Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review

Journal of Cardiothoracic Surgery
Background The management of hemostasis in patients medicated with apixaban (Eliquis) undergoing emergency cardiac surgery is exceedingly difficult. The body’s natural elimination pathways for apixaban prove ineffective in emergency situations, and the ...
Vitor Mendes, Jaid Mamode, Jalal Jolou, Mourad Malki, Christoph Ellenberger, Mustafa Cikirikcioglu, Christoph Huber   +6 more
doaj   +1 more source

Safety of Continuing Single‐Agent Antithrombotic Therapy During Emergency Cholecystectomy for Acute Cholecystitis: An Overlap‐Weighted Propensity Score Analysis With the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background/Purpose Optimal perioperative antithrombotic therapy (ATT) management during emergency cholecystectomy for acute cholecystitis remains controversial. We examined whether continuing single‐agent ATT is associated with hemorrhagic risk compared with no ATT.
Takeshi Tadokoro, Tomoyuki Abe, Masateru Yamamoto, Yuki Imaoka, Naruhiko Honmyo, Ryosuke Nakano, Seiichi Shimizu, Shintaro Kuroda, Hiroyuki Tahara, Masahiro Ohira, Tsuyoshi Kobayashi, Masakazu Hashimoto, Ko Oshita, Hiroshi Sakai, Michinori Hamaoka, Naoki Tanimine, Masashi Inoue, Tomoyuki Akita, Hideki Ohdan, Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)   +19 more
wiley   +1 more source